Adiponectinemia Is Associated with Uricemia but Not with Proinflammatory Status in Women with Metabolic Syndrome
Table 1
Clinical and laboratory characteristics of patients with metabolic syndrome and controls.
Metabolic Syndrome
Controls
Age (years)
45.0 (25.0β60.0)
41.5 (25.0β54.0)
0.1257
Smoking/no smoking
2/58
1/30
0.6379
BMI (m/kg2)
37.2 (27.1β53.9)
22.9 (20.1β24,5)
<0.0001
WC (cm)
110.0 (88.0β157.0)
79.0 (61.0β86.0)
<0.0001
SBP (mmHg)
134.5 (99.0β203.0)
101.0 (81.0β130.0)
<0.0001
DBP (mmHg)
83.0 (62.0β124.0)
65.0 (47.0β80.0)
<0.0001
Triacylg (mg/dL)
202.0 (40.0β401.0)
70.0 (32.0β135.0)
<0.0001
HDL (mg/dL)
39.0 (19.0β81.0)
58.5 (51.0β77.0)
<0.0001
Fasting glucose (mg/dL)
100.5 (74.0β195.0)
80.0 (71.0β93.0)
<0.0001
Fasting insulin (ΞΌU/mL)
18.50 (4.10β75.40)
4.40 (2.90β9.80)
<0.0001
HOMA
4.47 (0.83β36.24)
0.84 (0.57β1.79)
<0.0001
Uric acid (mg/dL)
5.51 (3.15β9.65)
3.38 (2.07β4.73)
<0.0001
Data are median (minimumβmaximum). BMI: body mass index; WC: waist circumference; SBP: systolic blood pressure; DBP: diastolic blood pressure; Triacylg: triacylglycerol; HDL: High-density lipoprotein; HOMA: Homeostasis model of assessment.